Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: mesaone who wrote (1174)	11/5/1998 12:53:00 PM
From: Jim Roof	Read Replies (1) \| Respond to of 1432

Asensio's release this morning is the reverse equivalent of an analyst hyping a stock just as it has topped out in hopes of liquidating his position into a last-gasp rally. I love it. Jim

To: mesaone who wrote (1174)	11/5/1998 4:21:00 PM
From: Jim Roof	Read Replies (1) \| Respond to of 1432

I just emailed my own report to Asensio. Shares of Biotime, Inc. traded up today in above average trading despite two negative 'reports' issued by Asensio & Company. It appears that BTIM's shares are in the hands of disciplined investors who have weathered worse storms in the past. Though BTIM initially traded as low as 11 1/4 it quickly rebounded to 12 1/2 on short covering. Asensio & Company has a history of establishing substantial short positions in companies whose products are under development and whose technology is not widely understood. It is this type of firm that Asensio can most easily hurt with his distorted, but well-timed 'research' reports. At face value it might seem as if Asensio is really a nice guy who likes to help out the unsuspecting investor by uncovering fraudulent practices. A closer look reveals that Asensio is as much a fraud, if not more so, than those on whom he dumps his rhetoric and distortions. It appears as if Asensio & Company has gone to this well one too many times. Biotime shares closed the day at 12 3/8 - up 5/8 despite two negative 'research reports' by Asensio & Company. Jim